Table of Contents
India’s Biological Regulatory landscape is at an inflection point. The country that pioneered affordable Biosimilar access, built one of the world’s largest vaccine manufacturing ecosystems, and established the framework for recombinant Biological oversight is now navigating a new wave of regulatory complexity — driven by CAR-T cell therapies, personalised medicine, AI-assisted Biological development, and the rapid evolution of advanced therapy medicinal products (ATMPs).
CDSCO, the RCGM, DBT, and the broader Indian regulatory community are responding with draft guideline revisions, new advisory committee frameworks, and regulatory modernisation initiatives that signal a fundamental transformation of how advanced Biologicals will be regulated in India over the next decade.
The most immediately impactful regulatory development is the ongoing revision of the Similar Biologics Guidelines — India’s primary biosimilar development and approval framework, originally published in 2012 and updated in 2016. The draft 2025 revision, anticipated for formal notification in 2026, is expected to introduce:
The draft guidelines represent a maturation of India’s biosimilar regulatory framework — moving from a prescriptive, stepwise approach to a science and risk-based model that rewards analytical characterisation quality.
India’s first domestic CAR-T cell therapy — NexCAR19 (actalycabtagene autoleucel) — was approved by CDSCO in October 2023, marking a watershed moment in India’s advanced therapy regulation. This approval demonstrated that India could evaluate and approve complex autologous cell therapies with a credible scientific framework and has catalysed significant regulatory thinking about systematically governing CAR-T and related ATMPs.
Several regulatory developments are anticipated:
In vivo gene therapies (AAV-based, LNP-delivered) and gene editing products challenge existing regulatory categories in India. CDSCO has not yet published specific guidance for in vivo gene therapy products — these are currently evaluated under the New Drug framework with RCGM and GEAC involvement. As the global pipeline matures and India-based gene therapy programmes develop, dedicated guidance will become necessary. Key future regulatory considerations include:
AI-driven protein design platforms are accelerating antibody and Biosimilar development — enabling in silico optimisation of immunogenicity, stability, and potency profiles. India’s growing biotechnology sector in Bengaluru and Hyderabad is beginning to leverage these platforms. CDSCO will increasingly encounter dossiers incorporating AI-generated data — requiring a regulatory stance on the evidentiary value and validation requirements for AI-derived evidence. The ICH M14 guideline on AI/ML in drug development, currently under development, will provide the international framework India is expected to adopt.
CDSCO has initiated exploratory work on AI tools for dossier review and adverse event signal detection through PvPI. AI-assisted review — analysing large clinical datasets, detecting dossier inconsistencies, and prioritising safety signals — has the potential to significantly accelerate review timelines and improve the quality of regulatory decisions.
India’s ambition to become a global biologics manufacturing hub is increasingly credible. Structural factors supporting this trajectory include:
CDSCO’s ongoing regulatory modernisation includes:
Saurangi is a food regulatory expert with 8 years of experience. She shares her knowledge and insights on regulatory updates, food trends, best practices, and news. Follow her for expert insights and practical advice on all things for food regulatory
CliniExperts Services Pvt. Ltd.
What a Revised Schedule M raises GMP standards in India, what has changed for manufacturers, and how large firms and MSMEs can prepare for Compliance and CDSCO inspections. Revised Schedule M is the b..
A practical comparison of CDSCO vs FDA vs EMA, explaining how each regulator’s Drug approval process differs and why one Drug needs separate approvals in India, the US and Europe. A Drug approve..
A quick guide on the Class A & B Medical Device manufacturing license — covering State FDA rules, Form MD-3/MD-5, fees, and timelines for manufacturers. Every manufacturer entering India’s..